Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATA 188

Drug Profile

ATA 188

Alternative Names: Allogeneic ATA 188; Allogeneic EBV-directed T-cell therapy; ATA-188; EBV-CTLs; EBV-targeted T-cell; Epstein-Barr Virus-directed cytotoxic T lymphocytes; Off-the-shelf ATA188

Latest Information Update: 07 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Atara Biotherapeutics
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Multiple sclerosis

Most Recent Events

  • 17 Jan 2024 Atara Biotherapeutics terminates a phase I/II EMBOLD trial in Multiple sclerosis (Treatment-experienced) in USA, Australia, and Canada (IV), due to the primary endpoint not being achieved (NCT03283826)
  • 11 May 2023 9388628: No updates
  • 26 Oct 2022 Updated efficacy data from a phase I/II EMBOLD trial in Multiple sclerosis presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top